BIOGNOSYS
19.5.2022 14:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005079/en/
Dr. Lüthi is Chief Executive Officer of CTC Analytics AG, a privately owned Swiss company leading in automation and advanced laboratory sample handling solutions for the pharmaceutical, life science, chemical, environmental, and food & flavor industries. Additionally, he holds several Board of Directors mandates in public firms, including Chairman of Inficon Group, Vice Chairman of Straumann Group, and Board Member of Skan AG.
Dr. Lüthi holds an M.Sc. in Electrical Engineering and a Ph.D. in Business Administration from ETH Zurich and completed an International Executive Program at the INSEAD Business School.
As Board Director at Biognosys, Dr. Lüthi will be instrumental in the company’s transformation to a leading provider and partner for protein insights to drive the development of new breakthrough treatments.
“I am excited to join Biognosys at a time when proteomics is widely adopted to accelerate life science research and development,” said Dr. Lüthi, incoming Board Director at Biognosys. “The company is at an inflection point of strengthening its global leadership position in the proteomics field and I am looking forward to being part of this journey.”
“I am delighted to welcome Dr. Lüthi as Board Director to support our next growth stage with his extensive experience as life sciences executive and board director,” commented Dr. Oliver Rinner, CEO of Biognosys. I would also like to thank our prior Board Director, Winfried Mayer, for his many years of invaluable service to our board.”
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
illumynt Launches Talorem®, Bringing Engineering Rigor to Smarter Technology Reuse6.10.2026 14:38:00 CEST | Press release
Proprietary technology platform delivers faster receiving, better asset intelligence, more accurate grading and higher recovery value. illumynt, a technology-driven lifecycle management company serving AI infrastructure, hyperscale, OEM and enterprise environments, today announced the launch of Talorem®, its proprietary technology platform designed to bring greater precision, intelligence and recovery value to the management of advanced computing assets. Talorem is illumynt’s proprietary technology platform for engineering-grade testing, refurbishment, recovery, grading and asset intelligence at scale. As the technology foundation behind illumynt’s advanced computing lifecycle operations, Talorem brings together OEM-grade testing and qualification, clean room component recovery, centralized grading infrastructure and analytics to create greater intelligence at every stage of the asset lifecycle-enabling faster processing, more accurate grading and higher recovery value. “Talorem repres
Corpay Cross-Border Extends Exclusive Partnership with WBSC6.10.2026 14:30:00 CEST | Press release
Corpay will continue to provide the World Baseball Softball Confederation access to innovative global payments and comprehensive currency risk management solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a long-term agreement to extend their successful and exclusive collaboration as the Official Foreign Exchange (FX) Payments Provider of the World Baseball Softball Confederation (WBSC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006279113/en/ Since 2022, Corpay Cross-Border has delivered a range of corporate foreign exchange payment solutions to the WBSC, the international governing body for Baseball/Softball. With this multi-year extension, the WBSC and their members around the globe will continue to benefit from Corpay’s comprehensive currency risk management solutions and award-winning global payments platform. “O
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 20266.10.2026 14:00:00 CEST | Press release
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrintTwo additional poster presentations from the FLEX Study Agendia, Inc., a leader in precision oncology for breast cancer, announced today that it will present new research during a podium presentation on the development of an artificial intelligence (AI)-driven digital pathology approach for MammaPrintⓇ at the European Society for Medical Oncology (ESMO) Congress 2026, which takes place October 23 to 27, 2026, in Madrid. The company will also present two additional posters at ESMO. AI-driven digital pathology approaches are rapidly developing to expand access to genomic testing globally. Agendia’s first presentation, submitted as a late-breaking abstract, focuses on the development and validation of an AI-driven MammaPrint approach based on the analysis of routine whole slide images of breast cancer tissue. The following are details of the late-breaking abstract t
ExaGrid Named Finalist for the MSP Channel Insights Awards 20266.10.2026 14:00:00 CEST | Press release
ExaGrid Nominated in 7 Categories for Industry Awards ExaGrid, the world’s largest independent backup storage vendor providing Tiered Backup Storage for the fastest backups and restores, largest scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in seven categories for the annual MSP Channel Insights Awards. The MSP Channel Insights Awards celebrate innovation, expertise and success across the IT channel—recognizing the Managed Service Providers (MSPs), vendors, distributors, resellers and technology leaders driving customer outcomes and business growth. Voting to determine the winner in each category is underway now and closes on October 30, 2026. Winners of the MSP Channel Insights Awards will be announced on November 26, 2026, at an awards ceremony in London. The award categories that ExaGrid has been nominated for include: Vendor of the Year Vendor Channel Pr
IFF Identifies the Life-Stage Insights Shaping Dairy’s Future6.10.2026 13:00:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005026164/en/ “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bakery, Bars and Confectionery) for IFF Taste. “Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives — and why.” Drawing on insights from Panoptic™, IFF's
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom